CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 27,400 shares, a growth of 1,422.2% from the September 15th total of 1,800 shares. Based on an average daily volume of 332,200 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 332,200 shares, the short-interest ratio is currently 0.1 days.
CSL Stock Up 1.1%
OTCMKTS CSLLY traded up $0.77 on Thursday, hitting $71.68. 220,330 shares of the stock were exchanged, compared to its average volume of 101,146. CSL has a fifty-two week low of $61.06 and a fifty-two week high of $101.44. The company has a 50-day moving average price of $71.13 and a 200-day moving average price of $76.76. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50.
Analyst Ratings Changes
CSLLY has been the subject of a number of research analyst reports. Zacks Research cut CSL from a "hold" rating to a "strong sell" rating in a report on Monday, September 15th. Canaccord Genuity Group raised shares of CSL to a "hold" rating in a research note on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, CSL has a consensus rating of "Hold".
Get Our Latest Report on CSL
About CSL
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.